Grifols International, S.A. news
Grifols has adopted a number of measures since the onset of the pandemic in order to respond to the needs of its stakeholders.
The company continually monitors the progression of COVID-19, analyzing and evaluating its potential impact on its workforce and operations to guarantee minimal delays or interruptions in our operations as Grifols’ products and services are essential for patients and healthcare professionals worldwide.
Day after day, at Grifols we continue
- Grifols increases its revenues by 12% to EUR 1,293 million
- The Bioscience Division leads growth, increasing revenues by 13.6% (10.9% cc) to EUR 1,040 million, driven mainly by the demand for strong key proteins, especially with immunoglobulins
- Diagnostic and Hospital Division revenues remain stable at EUR 168 million (1.4%; -0.3% cc) and EUR 31 million (0.6%; 0.8% cc), respectively. Bio Supplies revenues increase to EUR 64 million (24.5%; 21.9% cc)
Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare company with a track record of more than 100 years and a recognized leader in the development and production of plasma-derived medicines, today announced it has begun identifying, screening and selecting volunteer donors who have recovered from COVID-19 to donate their plasma in select U.S. cities.
The plasma will be used to produce a hyperimmune globulin that, if proven effective, could potentially treat the disease
- Grifols controls a 26.20% stake in Shanghai RAAS (economic and voting rights) in exchange for a non-majority share on behalf of Shanghai RAAS (45% economic rights and 40% voting rights) in Grifols’ subsidiary, Grifols Diagnostic Solutions (GDS)
- Over the past 35 years, Grifols has increasingly expanded its presence in China, which is currently the company’s third-largest sales market
- This transaction represents a unique opportunity for Grifols to reinforc
Grifols today announces that it has entered into a formal collaboration with the United States Biomedical Advanced Research Development Authority (BARDA), the Food and Drug Administration (FDA) and other Federal public health agencies to collect plasma from convalescent COVID-19 patients, process this specific plasma into a hyperimmune globulin and support the necessary preclinical and clinical studies to determine if anti-SARS-CoV-2 hyperimmune globulin therapy can successfully be used to tr
Grifols has adopted several measures aimed at reinforcing its strong commitment to its main stakeholders in regards to the new situation posed by the coronavirus (COVID-19) outbreak.
At Grifols, we believe this current and extraordinary situation requires companies to strive more than ever to serve patients and society in a responsible manner.
Grifols first responsibility is with its patients a
- A participant in the Profarma Plan since 1991, Grifols received the highest possible rating in 2019 in recognition of its solid commitment to R+D+i
- Grifols increased its R+D+i investments in 2019 by 12.9% to EUR 329 million, allocating a total of EUR 1,500 million to this area over the last five years
- The Profarma Plan is jointly managed by the Spanish Ministry of Economy, Industry and Competitiveness and Ministry of Health, Social Services and Equality to bo
- Revenue increases 13.6% (9.2% cc) as a result of the sustainable growth strategy, with advances in all divisions and regions
- Bioscience leads the growth with EUR 3,994 million of revenue (13.6%; 8.9% cc). Diagnostic and Hospital continue to make progress with sales of EUR 734 million (4.5%; 1.1% cc) and EUR 134 million (12.5%; 12.1% cc), respectively. Bio Supplies achieves EUR 267 million in revenues, growing by 59.6% (54.1% cc)
- Profitability improves: the un
- Grifols and the Public Investment Fund of Saudi Arabia (PIF) have executed a non-binding term sheet to build a network of plasma collection centers and other facilities for the production of plasma medicines, including a plasma fractionation plant and a purification plant, in Saudi Arabia.
- Following definitive agreements being signed, the project would be executed through
- Fourth straight year in which the prestigious healthcare research firm selects PharmacyKeeper Verification as the No. 1 Category Leader for Intravenous (IV) Workflow Management
- PharmacyKeeper Verification is a strategic part of Grifols’ inclusiv portfolio, offering integrated technology, software and service solutions dedicated to advancing quality and safety in pharmacy operations
Grifols (MCE:GRF, MCE:GRF.P NASD